ABBVIE WKN: A1J84E ISIN: US00287Y1091 Forum: Aktien Thema: Hauptdiskussion

Vielleicht die Chance fürs Äffchen ✌️

Kurzfristig könnte es nochmal runter gehen, gestern nach Börsenschluss folgende Meldung: AbbVie's Imbruvica flunks late-stage pancreatic cancer studyhttps://seekingalpha.com/news/3424405 Eine Phase III Studie hat nicht so angeschlagen wie gewollt, nachbörslich ging es etwas runter

Nach ausgiebiger Recherche, Cashbestand, Aussichten, Pipeline, bin ich mit erster Posi vorsichtig rein. Bin gespannt wie sich das auslaufen des Patents des Blockbusters auswirkt

Moin zusammen, Abbvie wird vielerorts empfohlen. In der aktuellen FOCUS-MONEY ist ein aktueller Artikel, Doppelseite. Eventuell stelle ich das mal rein.

Buy and hold.Anfangsrendite über 4% und starkes DividendenWachstum.Geht recht sicher so weiter-Tochter von Abbott (Aristokrat)

Dem Chart nach, könnte man sie auch gut traden

Tja Olli, hast mir die Perle einpaar Tage zu spät verraten;). Ich beobachte und könnte mir eine erste Position zwischen 74 und 75 vorstellen :)

Abbvie ist eine der besten Dividendenaktien am Markt.Klarer Kauf

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer $ABBVhttps://seekingalpha.com/pr/17385436

https://www.google.de/amp/s/seekingalpha.com/amp/article/4233472-abbvie-believes-life-humiras-death

https://www.google.de/amp/s/www.nasdaq.com/article/can-abbvie-abbv-keep-the-earnings-surprise-streak-alive-cm1084116/amp

Am 25.01.2019 kommen die Zahlen. Ob Abbvie wieder so überraschen wird können

The pessimism surrounding AbbVie has pushed its dividend yield to around 5%. The combination of a high yield, low valuation and solid growth prospects makes AbbVie a strong choice for any investor looking for current income, income growth and exposure to the pharmaceutical industry.

The company has invested heavily in its new product pipeline, spending between $4 billion and $5 billion a year on research and development in fiscal 2015 through fiscal 2017. The company is also engaging heavily in share repurchases. In addition to share repurchases, AbbVie also returns around 45% of earnings to shareholders via dividend payments.

AbbVie, one of the world’s largest biopharmaceutical companies, was created in 2013 when it was spun-off from Abbott Laboratories. The company has grown its adjusted earnings-per-share each year since it was spun off. From fiscal 2013 through fiscal 2017 adjusted earnings-per-share have compounded at a strong 15.6% rate. While AbbVie’s business results have been excellent, the market has not fully appreciated the stock. AbbVie generates nearly 60% of its revenue from the drug Humira. The drug has already begun to fall off the patent cliff, but results have been much better than previously thought. In fact, Humira sales are still growing as AbbVie both vigorously defends its patent position and continues to find new use cases for Humira.

Earnings over the next five years are expected to be even better than the last five. With a yield of 5%, the stock has a spectacular track record and offers more growth and a higher dividend than any other big drug company.